Testing INI-822 in healthy people and those with MASH
Part of Digestive system clinical trials.
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in good general health (or have MASH with specific test results).
- You need a recent FibroScan showing fat in your liver (at least 280 dB/m) and not too much scarring.
- Your liver enzyme level (ALT) must be above normal at least once in the past 6 months for MASH parts.
- You cannot have other liver diseases (like hepatitis B, C, or alcoholic liver disease).
- You must avoid alcohol during the study and limit it before visits.
- You cannot take certain medications that interact with the study drug (e.g., warfarin, some statins, antibiotics).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well different doses of a new drug (BI 3804379) are tolerated. It is for healthy people and for patients with MASH (a type of fatty liver disease) who have advanced liver scarring.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests a new drug, IMM-H014, for a liver condition called MASH (metabolic dysfunction-associated steatohepatitis). It looks at how well people tolerate the drug and how it works in the body. This might help if you have fat buildup in your liver along with other health issues like high blood pressure, diabetes, or high cholesterol.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.